Red Yeast Rice for Cholesterol
Red yeast rice genuinely lowers LDL cholesterol, but only because its active compound, monacolin K, is chemically identical to the prescription statin lovastatin. That means it carries the same muscle and liver risks as a statin, with none of the dosing consistency or oversight, which is why regulators treat high-monacolin products as unapproved drugs rather than supplements.
Why this grade7-layer evidence engine
The efficacy evidence is strong and consistent. Four high-quality meta-analyses agree it meaningfully reduces LDL cholesterol: a 6,663-patient pooled analysis found a placebo-subtracted LDL-C drop of 1.02 mmol/L, statistically indistinguishable from statin therapy (PMID 25897793), and later analyses reported LDL-C reductions of roughly 29 mg/dL (PMID 36259545) and 0.87 mmol/L (PMID 24897342), with 15 high-quality trials drawing similar conclusions (PMID 35111069). A large trial in post-myocardial-infarction patients even showed fewer coronary events (PMID 18549841), though that result comes from a single Chinese secondary-prevention population and cannot be generalized to ordinary primary prevention.
So why only a B grade rather than an A? The benefit is real, but it is a borrowed statin effect carrying statin-level hazards, and the product itself is unreliable. The active monacolin K is structurally identical to lovastatin, yet its content varies more than 60-fold between brands, so a given bottle may deliver a negligible dose or a drug-strength one. Some products are also contaminated with citrinin, a kidney-toxic mold byproduct.
Authorities reflect this tension. The US FDA treats red yeast rice containing more than trace monacolin K as an unapproved new drug, and EFSA could identify no safe intake, banning doses at or above 3 mg/day. Mayo Clinic and Cleveland Clinic stay cautious, noting it is not FDA-approved and can cause the same liver and muscle damage as statins; Cleveland Clinic's own SPORT trial found no significant LDL reduction versus placebo, likely because the commercial product's monacolin content was unknown. The verdict: it works, but 'natural' does not mean safe or predictable.
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditable▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.647
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高階證據未達主導 (1 positive vs 1 negative)，由 raw_score 決定
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status